Features | Partner Sites | Information | LinkXpress
Sign In

Thermo Fisher Scientific Showcases Expanded Offering for Clinical Laboratory

By Labmedica International staff writers
Posted on 29 Jul 2014
Image: Customers in clinical laboratories supporting hospitals, research institutions and government agencies are increasingly relying on ThermoFisher Scientific to achieve better diagnostics, improve patient care, and lower costs (Photo courtesy of Thermo Fisher Scientific).
Image: Customers in clinical laboratories supporting hospitals, research institutions and government agencies are increasingly relying on ThermoFisher Scientific to achieve better diagnostics, improve patient care, and lower costs (Photo courtesy of Thermo Fisher Scientific).
Thermo Fisher Scientific Inc. (Waltham, MA, USA) is introducing its Thermo Scientific and Life Technologies (Grand Island, NY, USA) products at the 2014 AACC Annual Meeting and Clinical Lab Expo. Thermo Fisher Scientific Inc. is highlighting its expanded portfolio of instruments, equipment, consumables, and software, for improving accuracy and efficiency in the clinical laboratory.

Marc N. Casper, president and CEO of Thermo Fisher Scientific comments “In the current healthcare environment, our customers in clinical laboratories supporting hospitals, research institutions, and government agencies are increasingly relying on better diagnostics to improve patient care and lower costs. We have the scale and depth of capabilities to help these customers drive accuracy and efficiency and ultimately improve the way healthcare is delivered.”

At AACC, Thermo Fisher will feature a range of products and services from its specialty diagnostics, analytical instrument, and genetic analysis portfolios including complete systems for aiding in the diagnosis of allergy and autoimmune diseases using ImmunoCAP and EliA blood tests such as the DRI Drugs of Abuse Assays, immunosuppressant assays, the CEDIA Cyclosporine Immunoassay, and the QMS Everolimus Immunoassay for therapeutic drug monitoring.

Next-generation sequencing platforms, including the Ion Torrent Personal Genome Machine and the Ion Chef automated sample preparation system for identifying genetic biomarkers of disease are also being shown. A new category of Thermo Scientific products, including high-performance liquid chromatography, mass spectrometry, and software designed and manufactured as US Food and Drug Association (FDA) Class 1 medical devices for use in laboratory-developed tests, and Thermo Scientific calibration and quality controls. In addition, the MAS LabLink Quality Assurance Program, a cloud-based application that offers an external perspective on daily QC and compares the data among peer laboratories will be revealed. Services including original equipment manufacturer (OEM) and custom services for development, manufacturing, and packaging of diagnostic products for third parties, as well as collaborative biomarker research and production services for industry and academia through the Thermo Fisher BRIMS center are introduced.

For a complete listing of products and services being showcased during AACC, please visit Thermo Fisher Scientific online (Please see Related Links below).

Related Links:

Thermo Fisher Scientific
Life Technologies



DIASYS DIAGNOSTIC SYSTEMS
77 ELEKTRONIKA
KARL HECHT GMBH & CO KG

Channels

Genetic Tests

view channel

Padlock Probe Assay Rapidly Detects Cardiac Disease Gene Mutations

A recent paper described a novel next generation sequencing (NGS) assay for detecting cardiac disease gene mutations with improved accuracy, flexibility, turnaround time, and cost. By using double-stranded DNA probes (complementary long "padlock" probes or cLPPs), investigators at Stanford University (Palo Alto, CA,... Read more

Hematology

view channel
Image: Immunochemistry of bone marrow biopsy from an acute myeloid leukemia patient showing sheets of CD34 positive cells; corresponding bone marrow aspirate showed only 20% blasts (Photo courtesy of All India Institute of Medical Sciences).

Immunohistochemistry Assesses Early Response in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to prognosis and early response assessment has an established role as predictor of remission rate, and overall and disease-free survival.... Read more

Industry News

view channel

Distribution Agreement to Improve Automated Hemostasis Diagnostics

A new, exclusive-distributer agreement will lead to creating a unique high-performance hemostatis work cell by connecting a laboratory automation system (LAS) from Thermo Fisher Scientific (Waltham, MA, USA) with a hemostasis testing LAS from Instrumentation Laboratory (IL; Bedford, MA, USA). The agreement between IL... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.